BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C

[at noodls] – Jerusalem – October 16, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, … more

View todays social media effects on BLRX

View the latest stocks trending across Twitter. Click to view dashboard